NAD+ and Longevity, Without the Sales Pitch

What NAD+ actually is, and what it does in the cell

NAD+ — nicotinamide adenine dinucleotide — is a coenzyme: a small molecule that other enzymes need in order to do their work. It is in every cell you have, and it has two jobs worth understanding separately.

The first is metabolic. NAD+ is the carrier that moves electrons out of the food you eat and into the chain that produces ATP, the cell's usable energy currency. Without it, energy metabolism does not run. That is not a wellness claim, it is textbook biochemistry, and it is why the word “energy” appears in every piece of NAD+ marketing ever written.

The second is regulatory. A family of enzymes — the sirtuins and the PARPs — use NAD+ as a substrate rather than merely borrowing it, which means they consume it. PARPs are involved in DNA repair. Sirtuins are involved in gene expression and metabolic regulation. Because these enzymes spend NAD+ rather than recycling it, heavy demand in one arm draws down the pool available to the other.

That is the entire mechanistic basis for the interest, and it is genuinely interesting. It is also a long way from a “youth molecule,” which is how it is usually sold.

The decline-with-age claim, and how well it holds up

That NAD+ falls with age is repeated so often it has acquired the texture of settled fact. It is better supported in some tissues than in others, and the human data is thinner than the confidence around it suggests.

Measuring NAD+ in a person is genuinely difficult. The molecule is unstable, levels differ between compartments — blood, skeletal muscle, skin, liver — and a sample starts degrading as soon as it is taken. Different laboratory methods produce different answers. Most of the human studies are small, and most compare younger people with older people at a single moment rather than following the same people as they age.

What can be said fairly: several human studies do find lower NAD+ in older tissue, particularly skin and muscle, and the direction is consistent enough to take seriously. What cannot be said: that there is an established normal range, that your own tissue level can be inferred from your age, or that any commercially available test will tell you your NAD+ status in a way that should drive a treatment decision. There is no such test in routine clinical use, and anyone selling one is ahead of the science.

Why precursors exist at all

NAD+ is a large, charged molecule, and cells do not simply take it up whole from the bloodstream. The evidence suggests extracellular NAD+ is largely taken apart at the cell surface, imported as smaller pieces, and rebuilt inside. That is the central awkwardness of this category: whatever you swallow or inject, what mostly crosses into the cell is not the thing you paid for.

Which is why the precursors exist. The body builds NAD+ by several routes. From tryptophan, an amino acid in ordinary protein, by a slow multi-step pathway. From niacin (vitamin B3), a recognized vitamin that has been in the food supply for decades. And from nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) through the salvage pathway, which is the main day-to-day route by which cells recycle what they already have.

The commercial interest is concentrated on NR and NMN because they sit only a step or two from NAD+ itself. It is worth noticing that niacin is old, cheap and unpatentable, and that NR and NMN are newer, proprietary and expensive. That does not make them worse. It does explain why you have heard of them.

What the human trials actually show

This is the section that decides everything else on the page, and it is the one that gets the least airtime elsewhere.

The precursors work as precursors. Randomized, placebo-controlled human trials of NR and NMN consistently show that taking them raises measured NAD+ in blood, and that the rise tracks with how much is taken. That finding is solid and reproducible. If the question is “can you move the number,” the answer is yes.

What has not reliably followed is a clinical benefit. Those trials have looked at insulin sensitivity, muscle strength and function, walking distance, fatigue, blood pressure, inflammatory markers and cognition, in older adults, in people with metabolic problems, and in athletes. The results are mixed. Where an effect is found it tends to be small, the studies are short — weeks to a few months — and the participant numbers are low. A signal that appears in one trial often fails to reappear in the next trial of the same compound.

So the honest summary is two sentences long. Raising the level is established. Turning that into something you can feel, or that a clinician can measure on you, is not. A biomarker moving is not a benefit, and the gap between those two facts is exactly where the commercial category has set up shop.

Injection or supplement: less settled than either side admits

The case for injecting is absorption. Swallowing NAD+ itself is a poor idea on the face of it — it is broken down in digestion before it goes anywhere useful. An injection bypasses the gut entirely, and produces a blood level far above anything an oral route achieves, at least briefly. That is a real pharmacokinetic difference, not a marketing one.

The case against is what happens next. Circulating NAD+ is degraded quickly and enters cells largely as its breakdown products — which is roughly what an oral precursor delivers anyway, by a slower and cheaper route. And the human trial evidence described above was almost entirely generated with oral precursors. There is very little controlled human data on injected NAD+ at all, and effectively none comparing it head-to-head with an oral precursor on any outcome a patient would care about.

So the question is open, and it should be stated as open. Anyone telling you the injection is definitively better is extrapolating from a mechanism argument. Anyone telling you it cannot possibly do anything is doing the same thing in the opposite direction. The comparison has not been run.

The regulatory picture, including the NMN oddity

NAD+ injections are compounded preparations and are not FDA-approved for any use. An FDA-approved drug has been through a review process for a specific indication, with the trial evidence that requires. A compounded preparation has not. Prescribing one is a clinical judgment made for an individual patient, and it is not a regulatory endorsement of anything.

NMN carries an oddity of its own. In 2022 the FDA took the position that NMN is excluded from the statutory definition of a dietary supplement, on the basis that it had already been authorized for investigation as a new drug. The practical result is a compound sold widely online whose standing as a supplement is contested. NR is not in that position. Niacin is a vitamin and has never been in question.

None of this tells you whether anything works — regulatory status and efficacy are different questions. It is worth knowing anyway, because the phrase “FDA-approved” turns up in longevity marketing in ways that do not survive reading the label.

What the subjective reports are worth

People do report feeling better. Clearer, more energetic, sleeping more soundly. Those reports are real in the sense that matters most — the person is telling you the truth about their experience. They are also close to worthless as evidence, and it is worth being precise about why rather than waving at the word placebo.

Placebo responses are largest for exactly the outcomes this category sells: energy, mood, focus, general wellbeing. They are amplified by price, by ritual, by the effort of making the trip, by sitting still under the care of a clinician for an hour, and by having decided in advance that this would help. Someone who has paid a lot and gone out of their way is the textbook setup for a large one.

Two more things pull in the same direction. People start these programs at a low point, because a low point is what prompts the search — and low points tend to drift back toward the person's own average without any help. And almost nobody starts an infusion in isolation; it usually arrives alongside better sleep, a new training effort, or a decision to take their health seriously.

That does not mean nothing is happening. It means personal testimony cannot tell the difference between the compound working and the circumstances working. Only a controlled trial can do that, and for injected NAD+ that trial has not been done.

The adjacent injectables: B12 and glutathione

The same clinics tend to offer the same short list beside NAD+, and the evidence behind each part of it is very different. Lumping them together is how a strong case gets used to carry a weak one.

B12 is the firmest ground here. Deficiency is real, common enough after 45 to be worth looking for, and measurable on a blood test. Reduced stomach acid with age, metformin, long-term acid-suppressing medication, a diet with little or no animal protein and pernicious anemia all cause it. Left alone it produces anemia and a specific neurological picture that is not always fully reversible, and treating it is straightforward, cheap and well established. The route question is narrower than the marketing implies: where the problem is intake, tablets generally work; where the problem is absorption — pernicious anemia, or surgery affecting the stomach or ileum — the injection exists for a reason.

What B12 does not do is give energy to someone who already has enough of it. Supplementing a person whose level is comfortably normal produces no benefit at all. Which is why the answer to “should I be getting B12 shots?” starts with a blood test rather than a booking.

Glutathione is thinner ground again. That it is the body's principal intracellular antioxidant is not in dispute. Whether giving it from outside changes anything is. Swallowed glutathione is largely dismantled in digestion into its component amino acids; injected glutathione does reach the bloodstream, but the human outcome evidence is sparse, and a good deal of what exists concerns skin pigmentation rather than anything in this conversation. For an adult in midlife hoping for an antioxidant or detoxification benefit, there is no good human trial evidence that an injection delivers one.

The same test is worth applying to DHEA and pregnenolone, which sit in the same corner of the market. DHEA is a measurable hormone with a narrow evidence base and specific situations where a clinician may look at it. Pregnenolone is mostly claims.

What actually has strong evidence for healthspan

If the goal is healthspan — more years spent in decent working order — the evidence is not evenly distributed across the options, and it is not close.

Sleep, in enough quantity and reasonable quality, including finding out whether you have undiagnosed sleep apnea. Resistance training, which is the single most reliable intervention available against the thing that actually takes away independence later, which is losing muscle and strength. Enough protein to support that training. Cardiovascular risk management — blood pressure, ApoB, Lp(a), glucose and insulin — every one of which is measurable now and treatable now. Not smoking. Alcohol on the low side. Staying connected to other people.

Every item on that list is supported by human evidence of a quality that nothing injectable in the longevity category comes close to matching. Several of them are free. None of them is interesting to write marketing copy about, which is a large part of why the marketing is about NAD+ instead.

So here is the most useful sentence on this page. If those fundamentals are not in place, no infusion will make up the difference, and the money is better spent almost anywhere else. If they are in place and you are still curious about NAD+, that is a perfectly reasonable position to hold — it is simply a different one from the position most people are in when they first go looking.

Where that leaves the decision

A defensible way to approach this starts with measurement rather than with a product. Fatigue has a long list of common, boring, measurable causes — thyroid function, iron, B12, glucose and insulin, sleep apnea, testosterone, depression — and several of them have better answers than anything on this page. A baseline panel is what separates them.

If NAD+ is still of interest after that, the honest framing is a trial with a defined endpoint and a date to review it, rather than a subscription that renews while nobody is looking. And it is worth being clear about what is being bought: a compounded preparation, not FDA-approved, with a mechanistic rationale that is sound and a clinical evidence base that has not arrived yet.

That is not a reason nobody should ever try it. It is a reason nobody should be told it is proven.

Frequently asked questions